Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • News
    • Cardiac Sciences
    • Beta-blockers have no...

    Beta-blockers have no survival benefit beyond 1 year in Post MI stable CAD

    Written by Vinay Singh singh Published On 2019-01-17T20:10:30+05:30  |  Updated On 17 Jan 2019 8:10 PM IST
    Beta-blockers have no survival benefit beyond 1 year in Post MI  stable CAD

    A new study published in the European Heart Journal has reported that beta-blockers have no impact on mortality beyond 1 year in post-MI stable CAD patients and offer no survival benefit in stable patients who have not had a myocardial infarction. The study also revealed that calcium channel blockers (CCBs) offered no protection against mortality at any time point. These drugs may be used for symptom treatment though mortality benefit may not be present.


    β-blockers and calcium antagonists are recommended for the treatment of angina in patients with stable coronary artery disease (CAD). They are widely used in stable CAD, including angina-free patients even though their role in improving outcomes remains uncertain.


    Read Also: Pesticides exposure at workplace doubles risk of coronary artery disease


    Randomized clinical trials (RCTs) established unequivocal benefits of β-blockers in chronic heart failure with left ventricular (LV) systolic dysfunction and in relatively old trials in acute myocardial infarction (MI), but no trials assessed their benefit compared with placebo in stable CAD.


    Sorbets and associates conducted a post hoc analysis of the CLARIFY (prospeCtive observational LongtudinAl RegIstry oF patients with stable coronary arterY disease) registry to evaluate the association between beta-blocker or calcium antagonist use and clinical outcomes.


    Patients with ≥1 of the following criteria were eligible for enrollment: documented myocardial infarction (MI) >3 months prior; coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) >3 months prior; chest pain with proven myocardial ischemia; and prior coronary angiography with ≥1 coronary stenosis >50%. Exclusion criteria were hospitalization for cardiovascular disease within 3 months of planned enrollment, planned revascularization, and conditions that would interfere with life expectancy (e.g., severe heart failure).


    The primary outcome was all-cause mortality. Secondary outcomes were cardiovascular mortality and the composite of cardiovascular mortality/non-fatal MI.


    Read Also: First Ever Test That predicts risk of MI in Coronary artery disease


    The key study findings included were:




    • The investigators found that among patients not receiving Beta-blockers, approximately 40% had a prior history of intolerance or a contraindication to beta-blockers.

    • Of the patients receiving beta-blockers, 45.1% received less than half of target dose, 41.5% half to less than full dose, and 13.3% the full target dose.

    • The rate of death was 1.80 per 100 patient-years. For the primary and secondary outcomes, multivariable-adjusted HRs showed no association between beta-blocker use at baseline and outcomes.

    • Among patients with MI ≤1 year prior to enrollment, beta-blocker use compared to nonuse was associated with a lower risk of all-cause mortality, lower cardiovascular mortality, and lower cardiovascular mortality/nonfatal MI.

    • In patients with prior MI >1 year, there was no difference in outcomes between groups.

    • Calcium antagonists were used in 5,885 (26.7%) patients. Among users, ~80% received long-acting dihydropyridines, ~15% received diltiazem, and ~5% received verapamil.

    • Multivariable-adjusted HR for the primary and secondary outcomes showed no association between calcium antagonist use at baseline and any outcome, regardless of time from MI to enrollment.


    The study concluded that β-blocker use was associated with lower 5-year mortality only in patients enrolled in the year following MI. Use of calcium antagonists was not associated with superior mortality, regardless of history of MI.


    For full information log on to https://doi.org/10.1093/eurheartj/ehy811

    betabeta blockersbeyond 1 yearblockerCABGCADCalciumcardiovascularchannelCLARIFYcoronary artery bypass graftingCoronary artery diseaseEuropean Heart JournalleftMImortalitymyocardial infarctionno survival benefitpoststableStable CADSuperiorventricleverapamil
    Source : With inputs from European Heart Journal

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Vinay Singh singh
    Vinay Singh singh
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok